Includes ESG Management Status and Achievements Across Environmental, Social, and Governance Sectors

Aiming to Become a Sustainable Healthcare Company that Creates Social Value

ILDONG Pharmaceutical (CEO Woongsup Yun) has published its 2025 Sustainability Report, outlining key aspects and directions of its ESG (Environmental, Social, and Governance) management, with the goal of realizing its vision of becoming a “sustainable healthcare company that creates social value.”

The company explained that the report was published to transparently disclose major activities, achievements, and mid-to-long-term strategies related to ESG management, and to actively engage with stakeholders.

This report covers the period from January to December 2024 and is structured around the company’s:

• ESG management framework and performance,

• Status in each ESG category (Environment, Social, Governance),

• Related data and appendices.

It was prepared in accordance with major ESG standards and guidelines, including the GRI Standards, TCFD, and SASB.

In addition, the report includes company-wide activities, results, and mid-to-long-term implementation plans for five key ESG issues, which were identified through stakeholder engagement and materiality assessment:

1. New product and new business development

2. Human resource enhancement

3. Human rights management

4. Quality and safety management

5. Climate crisis response

In the environmental sector, ILDONG focused on addressing climate change and carbon emissions. In 2024, it installed a solar power generation system at its Cheongju plant and participated in biodiversity conservation campaigns.

In the social sector, the company reinforced its efforts both internally and externally—strengthening talent and human rights management, occupational safety and health, and corporate culture, while also engaging in community contributions such as donations and sponsorships, and enhancing quality management.

In terms of governance, ILDONG worked to enhance transparency and strengthen communication and trust with stakeholders. Starting last year, the company expanded its disclosure of governance-related information, including the publication of a governance report. It also significantly improved its compliance with core governance indicators, in line with its commitment to responsible management and increasing shareholder value and rights.

ILDONG Pharmaceutical stated that it will continue to strengthen and advance its ESG management practices across the organization, in order to effectively respond to market conditions and risks, meet stakeholder expectations, and grow into a sustainable company with a virtuous business cycle.